Transdermal Drug Delivery System Market Overview ,Industry Analysis And Forecast To 2024| Grand View Research, Inc
“The global Transdermal Drug Delivery System Market accounted for USD 31.6 billion in 2015.�
Global transdermal drug delivery system market is expected to reach USD 81.4 billion by 2024, according to a new report by Grand View Research, Inc. The unprecedented global shift in the adoption of unhealthy lifestyles is presumed to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in the future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases are expected to propel the demand for highly efficacious pharmacological drugs. The market is driven by technological advancements in transdermal drug delivery devices, which is anticipated to serve the market with future growth opportunities. These advancements include advanced, third-generation, transdermal drug delivery technologies including iontophoresis, ultrasound, and microneedles or mechanical arrays. These technologies serve as effective transdermal drug diffusion alternatives that are capable of improving overall patient health and quality of life. For instance, the advent of matrix-controlled transdermal drug diffusion comprising a drug reservoir and a thermo effector, enhances skin permeation and enables controlled drug delivery. Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/transdermal-drug-deliverysystems-industry
Follow Us:
Further key findings from the study suggest:
The cardiovascular application segment is expected to exhibit growth at a significant CAGR of over 12.0% during the forecast period. This is a consequence of the high clinical urgency to curb hypertension and the need for precise drug delivery at a constant rate, which has led to the development of transdermal drug delivery systems.
The mechanical array in the technology segment is anticipated to witness an exponential CAGR of over 12.5%. The lucrative growth is attributed to the availability of different forms of microneedle transdermal systems, such as solid, hollow, and dissolving microneedles, as per the suitability and needs of the patients.
In 2015, North America dominated the overall Transdermal Drug Delivery System Market at over 50.0%. The consistent number of product launches being undertaken and the continual participation of the prominent players in conducting clinical trials are anticipated to promote the incorporation of transdermal drug delivery systems.
The key players are increasingly involved in initiating collaborative strategies and frequent product launches to capture a larger market share. For instance, in September 2014, Noven Pharmaceuticals, Inc. received the FDA approval for Minivelle, estradiol transdermal system to be used for the prevention of postmenopausal osteoporosis. Furthermore, in June 2015, Boehringer Ingelheim GmbH sponsored the clinical trials, which investigated the bioequivalence of transdermal clonidine administration.
Grand View Research has segmented the transdermal drug delivery system market on the basis of technology, application, and region: Global Transdermal Drug Delivery Systems Product Outlook (Revenue, USD Billion, 2013 - 2024) Electroporation
Radiofrequency
Iontophoresis
Microporation
Thermal
Mechanical arrays
Ultrasound
Others
Global Transdermal Drug Delivery Systems Application Outlook (Revenue, USD Billion, 2013 - 2024) Central nervous system
Pain management
Cardiovascular
Hormone
Others
Follow Us:
Transdermal Drug Delivery Systems Regional Outlook (Revenue, USD Billion, 2013 - 2024) North America
o
U.S.
o
Canada
Europe o
UK
o
Germany
Asia Pacific o
Japan
o
China
o
India
Latin America o
Mexico
o
Brazil
MEA o
South Africa
Browse Related Category Reports @ https://www.grandviewresearch.com/industry/medical-devices Table of Content of Transdermal Drug Delivery Systems Market Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources Chapter 2. Executive Summary Chapter 3. Market Snapshot Chapter 4. Market Variables, Trends & Scope 4.1. Market segmentation & scope 4.2. Market Driver Analysis 4.3. Market Restraint Analysis 4.4. Penetration & growth prospect mapping 4.5. Transdermal drug delivery systems-SWOT Analysis, By Factor (political & legal, economic and
Follow Us:
technological) 4.6. Industry Analysis - Porter's Chapter 5. Market Categorization 1: Technology Estimates & Trend Analysis 5.1. Transdermal Drug Delivery System Market: Technology Movement Analysis 5.2. Electroporation 5.2.1. Electroporation market estimates and forecasts, 2013 - 2024 (USD Billion) 5.3. Radiofrequency 5.3.1. Radiofrequency market estimates and forecasts, 2013 - 2024 (USD Billion) 5.4. Iontophoresis 5.4.1. Iontophoresis market estimates and forecasts, 2013 - 2024 (USD Billion) 5.5. Microporation 5.5.1. Microporation market estimates and forecasts, 2013 - 2024 (USD Billion) 5.6. Thermal 5.6.1. Thermal market estimates and forecasts, 2013 - 2024 (USD Billion) 5.7. Mechanical Arrays 5.7.1. Mechanical arrays market estimates and forecasts, 2013 - 2024 (USD Billion) 5.8. Ultrasound 5.8.1. Ultrasound market estimates and forecasts, 2013 - 2024 (USD Billion) 5.9. Others 5.9.1. Others market estimates and forecasts, 2013 - 2024 (USD Billion) Chapter 6. Market Categorization 2: Application Estimates & Trend Analysis 6.1. Transdermal Drug Delivery System Market: Application Movement Analysis 6.2. CNS 6.2.1. CNS market estimates and forecasts, 2013 - 2024 (USD Billion) 6.3. Pain Management 6.3.1. Pain management market estimates and forecasts, 2013 - 2024 (USD Billion) 6.4. Cardiovascular 6.4.1. Cardiovascular market estimates and forecasts, 2013 - 2024 (USD Billion) 6.5. Hormone 6.5.1. Hormone market estimates and forecasts, 2013 - 2024 (USD Billion) 6.6. Others 6.6.1. Others Market Estimates and Forecasts, 2013 - 2024 (USD Billion)
Follow Us:
Chapter 7. Market Categorization 3: Regional Estimates & Trend Analysis, By Technology & Application 7.1. Transdermal Drug Delivery System Market Share By Region, 2015 & 2024 7.2. North America 7.2.1. North America market estimates and forecasts, by technology, 2013 - 2024 (USD Billion) 7.2.1.1. U.S. market estimates and forecasts 7.2.1.2. Canada market estimates and forecasts 7.2.2. North America market estimates and forecasts, by application, 2013 - 2024 (USD Billion) 7.2.2.1. U.S. market estimates and forecasts 7.2.2.2. Canada market estimates and forecasts 7.3. Europe 7.3.1. Europe market estimates and forecasts, by technology, 2013 - 2024 (USD Billion) 7.3.1.1. UK market estimates and forecasts 7.3.1.2. Germany market estimates and forecasts 7.3.2. Europe market estimates and forecasts, by application, 2013 - 2024 (USD Billion) 7.3.2.1. UK market estimates and forecasts 7.3.2.2. Germany market estimates and forecasts 7.4. Asia Pacific 7.4.1. Asia Pacific market estimates and forecasts, by technology, 2013 - 2024 (USD Billion) 7.4.1.1. Japan market estimates and forecasts 7.4.1.2. China market estimates and forecasts 7.4.1.3. India market estimates and forecasts 7.4.2. Asia Pacific market estimates and forecasts, by application, 2013 - 2024 (USD Billion) 7.4.2.1. Japan market estimates and forecasts 7.4.2.2. China market estimates and forecasts 7.4.2.3. India market estimates and forecasts 7.5. Latin America 7.5.1. Latin America market estimates and forecasts, by technology, 2013 - 2024 (USD Billion) 7.5.1.1. Brazil market estimates and forecasts 7.5.1.2. Mexico market estimates and forecasts 7.5.2. Latin America market estimates and forecasts, by application, 2013 - 2024 (USD Billion) 7.5.2.1. Brazil market estimates and forecasts 7.5.2.2. Mexico market estimates and forecasts
Follow Us:
7.6. MEA 7.6.1. MEA market estimates and forecasts, by technology, 2013 - 2024 (USD Billion) 7.6.1.1. South Africa market estimates and forecasts 7.6.2. MEA market estimates and forecasts, by application, 2013 - 2024 (USD Billion) 7.6.2.1. South Africa market estimates and forecasts Chapter 8. Competitive Landscape 8.1. Strategy framework 8.2. Market participation categorization 8.3. Company Profiles 8.3.1. Novartis AG 8.3.1.1. Company overview 8.3.1.2. Financial performance 8.3.1.3. Product benchmarking 8.3.1.4. Strategic initiatives 8.3.2. Johnson & Johnson 8.3.2.1. Company overview 8.3.2.2. Financial performance 8.3.2.3. Product benchmarking 8.3.2.4. Strategic initiatives 8.3.3. Mylan Pharmaceuticals, Inc 8.3.3.1. Company overview 8.3.3.2. Financial performance 8.3.3.3. Product benchmarking 8.3.3.4. Strategic initiatives 8.3.4. Boehringer Ingelheim GmbH 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Product benchmarking 8.3.4.4. Strategic initiatives 8.3.5. Biogel Technology, Inc. 8.3.5.1. Company overview 8.3.5.2. Financial performance
Follow Us:
8.3.5.3. Product benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Transdermal Technologies, Inc. 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Product benchmarking 8.3.6.4. Strategic initiatives 8.3.7. Skyepharma PLC 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Product benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Watson Pharmaceuticals, Inc 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Product benchmarking 8.3.8.4. Strategic initiatives 8.3.9. 3M Company 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Product benchmarking 8.3.9.4. Strategic initiatives 8.3.10. Noven Pharmaceuticals, Inc 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Product benchmarking 8.3.10.4. Strategic initiatives 8.3.11. 4P Therapeutics, LLC 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Product benchmarking 8.3.11.4. Strategic initiatives
Follow Us:
8.3.12. Echo Therapeutics, Inc 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Product benchmarking 8.3.12.4. Strategic initiatives 8.3.13. Transdermal Corp 8.3.13.1. Company overview 8.3.13.2. Financial performance 8.3.13.3. Product benchmarking 8.3.13.4. Strategic initiatives
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com
Follow Us: